0000811222
false
--12-31
2023
Q2
0000811222
2023-01-01
2023-06-30
0000811222
dei:FormerAddressMember
2023-01-01
2023-06-30
0000811222
2023-06-30
0000811222
2022-12-31
0000811222
CDIF:SeriesNSeniorConvertiblePreferredStockMember
2023-06-30
0000811222
CDIF:SeriesNSeniorConvertiblePreferredStockMember
2022-12-31
0000811222
CDIF:SeriesXSeniorConvertiblePreferredStockMember
2023-06-30
0000811222
CDIF:SeriesXSeniorConvertiblePreferredStockMember
2022-12-31
0000811222
us-gaap:SeriesBPreferredStockMember
2023-06-30
0000811222
us-gaap:SeriesBPreferredStockMember
2022-12-31
0000811222
us-gaap:SeriesCPreferredStockMember
2023-06-30
0000811222
us-gaap:SeriesCPreferredStockMember
2022-12-31
0000811222
us-gaap:SeriesEPreferredStockMember
2023-06-30
0000811222
us-gaap:SeriesEPreferredStockMember
2022-12-31
0000811222
CDIF:SeriesF1PreferredStockMember
2023-06-30
0000811222
CDIF:SeriesF1PreferredStockMember
2022-12-31
0000811222
CDIF:SeriesIPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesIPreferredStockMember
2022-12-31
0000811222
CDIF:SeriesJPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesJPreferredStockMember
2022-12-31
0000811222
CDIF:SeriesLPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesLPreferredStockMember
2022-12-31
0000811222
CDIF:SeriesRPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesRPreferredStockMember
2022-12-31
0000811222
CDIF:SeriesNPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesNPreferredStockMember
2022-12-31
0000811222
CDIF:SeriesXPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesXPreferredStockMember
2022-12-31
0000811222
2023-04-01
2023-06-30
0000811222
2022-04-01
2022-06-30
0000811222
2022-01-01
2022-06-30
0000811222
us-gaap:FinancialServiceMember
2023-04-01
2023-06-30
0000811222
us-gaap:FinancialServiceMember
2022-04-01
2022-06-30
0000811222
us-gaap:FinancialServiceMember
2023-01-01
2023-06-30
0000811222
us-gaap:FinancialServiceMember
2022-01-01
2022-06-30
0000811222
CDIF:HealthcareSegmentMember
2023-04-01
2023-06-30
0000811222
CDIF:HealthcareSegmentMember
2022-04-01
2022-06-30
0000811222
CDIF:HealthcareSegmentMember
2023-01-01
2023-06-30
0000811222
CDIF:HealthcareSegmentMember
2022-01-01
2022-06-30
0000811222
CDIF:PreferredStockSeriesAIKMember
2021-12-31
0000811222
CDIF:PreferredStockSeriesBDEFF1GHLMember
2021-12-31
0000811222
CDIF:PreferredStockSeriesCAndRMember
2021-12-31
0000811222
us-gaap:TreasuryStockCommonMember
2021-12-31
0000811222
CDIF:PreferredStockSeriesAIKMember
2022-12-31
0000811222
CDIF:PreferredStockSeriesBDEFF1GHLMember
2022-12-31
0000811222
CDIF:PreferredStockSeriesCAndRMember
2022-12-31
0000811222
us-gaap:TreasuryStockCommonMember
2022-12-31
0000811222
us-gaap:CommonStockMember
2021-12-31
0000811222
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0000811222
us-gaap:RetainedEarningsMember
2021-12-31
0000811222
2021-12-31
0000811222
us-gaap:CommonStockMember
2022-12-31
0000811222
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0000811222
us-gaap:RetainedEarningsMember
2022-12-31
0000811222
CDIF:PreferredStockSeriesAIKMember
2022-01-01
2022-06-30
0000811222
CDIF:PreferredStockSeriesBDEFF1GHLMember
2022-01-01
2022-06-30
0000811222
CDIF:PreferredStockSeriesCAndRMember
2022-01-01
2022-06-30
0000811222
us-gaap:TreasuryStockCommonMember
2022-01-01
2022-06-30
0000811222
CDIF:PreferredStockSeriesAIKMember
2023-01-01
2023-06-30
0000811222
CDIF:PreferredStockSeriesBDEFF1GHLMember
2023-01-01
2023-06-30
0000811222
CDIF:PreferredStockSeriesCAndRMember
2023-01-01
2023-06-30
0000811222
us-gaap:TreasuryStockCommonMember
2023-01-01
2023-06-30
0000811222
us-gaap:CommonStockMember
2022-01-01
2022-06-30
0000811222
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-06-30
0000811222
us-gaap:RetainedEarningsMember
2022-01-01
2022-06-30
0000811222
us-gaap:CommonStockMember
2023-01-01
2023-06-30
0000811222
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-06-30
0000811222
us-gaap:RetainedEarningsMember
2023-01-01
2023-06-30
0000811222
CDIF:PreferredStockSeriesAIKMember
2022-06-30
0000811222
CDIF:PreferredStockSeriesBDEFF1GHLMember
2022-06-30
0000811222
CDIF:PreferredStockSeriesCAndRMember
2022-06-30
0000811222
us-gaap:TreasuryStockCommonMember
2022-06-30
0000811222
CDIF:PreferredStockSeriesAIKMember
2023-06-30
0000811222
CDIF:PreferredStockSeriesBDEFF1GHLMember
2023-06-30
0000811222
CDIF:PreferredStockSeriesCAndRMember
2023-06-30
0000811222
us-gaap:TreasuryStockCommonMember
2023-06-30
0000811222
us-gaap:CommonStockMember
2022-06-30
0000811222
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0000811222
us-gaap:RetainedEarningsMember
2022-06-30
0000811222
2022-06-30
0000811222
us-gaap:CommonStockMember
2023-06-30
0000811222
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0000811222
us-gaap:RetainedEarningsMember
2023-06-30
0000811222
us-gaap:EquipmentMember
2023-01-01
2023-06-30
0000811222
CDIF:MedicalEquipmentMember
2023-01-01
2023-06-30
0000811222
us-gaap:LeaseholdImprovementsMember
2023-01-01
2023-06-30
0000811222
srt:ScenarioPreviouslyReportedMember
2022-06-30
0000811222
srt:RestatementAdjustmentMember
2022-06-30
0000811222
CDIF:AsRestatedMember
2022-06-30
0000811222
srt:ScenarioPreviouslyReportedMember
2022-04-01
2022-06-30
0000811222
srt:RestatementAdjustmentMember
2022-04-01
2022-06-30
0000811222
CDIF:AsRestatedMember
2022-04-01
2022-06-30
0000811222
srt:ScenarioPreviouslyReportedMember
2022-01-01
2022-06-30
0000811222
srt:RestatementAdjustmentMember
2022-01-01
2022-06-30
0000811222
CDIF:AsRestatedMember
2022-01-01
2022-06-30
0000811222
2022-01-01
2022-12-31
0000811222
CDIF:ManagerOfPlatinumTaxMember
2023-06-30
0000811222
CDIF:ManagerOfPlatinumTaxMember
2022-12-31
0000811222
CDIF:PreviousOwnersOfEdgeViewMember
2023-06-30
0000811222
CDIF:PreviousOwnersOfEdgeViewMember
2022-12-31
0000811222
CDIF:ChairmanMember
2023-06-30
0000811222
CDIF:ChairmanMember
2022-12-31
0000811222
CDIF:LoansAndNotesPayableMember
2023-06-30
0000811222
CDIF:LoansAndNotesPayableMember
2022-12-31
0000811222
CDIF:SBALoanMember
2020-06-01
2020-06-02
0000811222
CDIF:SBALoanMember
2023-06-30
0000811222
CDIF:SBALoanMember
2022-12-31
0000811222
us-gaap:ConvertibleNotesPayableMember
2023-01-01
2023-06-30
0000811222
us-gaap:ConvertibleNotesPayableMember
2022-01-01
2022-06-30
0000811222
CDIF:SecurityExchangeAndPurchaseAgreementMember
2022-09-21
2022-09-22
0000811222
CDIF:SeriesXSeniorConvertiblePreferredStockMember
2022-09-21
2022-09-22
0000811222
CDIF:SeriesXSeniorConvertiblePreferredStockMember
2022-09-22
0000811222
CDIF:PromissoryNoteMember
2022-09-22
0000811222
CDIF:PromissoryNoteMember
2022-09-21
2022-09-22
0000811222
CDIF:ConvertibleNote40Member
2023-06-05
0000811222
CDIF:ConvertibleNote40Member
2023-06-13
0000811222
CDIF:ConvertibleNote40Member
2023-06-04
2023-06-05
0000811222
CDIF:ConvertibleNote40Member
2023-06-12
2023-06-13
0000811222
CDIF:ConvertibleNotesPayablesMember
2023-06-30
0000811222
CDIF:ConvertibleNotesPayablesMember
2022-12-31
0000811222
CDIF:ConvertibleNote71Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote71Member
2022-12-31
0000811222
CDIF:ConvertibleNote71Member
2023-06-30
0000811222
CDIF:ConvertibleNote9Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote9Member
2022-12-31
0000811222
CDIF:ConvertibleNote9Member
2023-06-30
0000811222
CDIF:ConvertibleNote10Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote10Member
2022-12-31
0000811222
CDIF:ConvertibleNote10Member
2023-06-30
0000811222
CDIF:ConvertibleNote101Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote101Member
2022-12-31
0000811222
CDIF:ConvertibleNote101Member
2023-06-30
0000811222
CDIF:ConvertibleNote102Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote102Member
2022-12-31
0000811222
CDIF:ConvertibleNote102Member
2023-06-30
0000811222
CDIF:ConvertibleNote292Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote292Member
2022-12-31
0000811222
CDIF:ConvertibleNote292Member
2023-06-30
0000811222
CDIF:ConvertibleNote31Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote31Member
2022-12-31
0000811222
CDIF:ConvertibleNote31Member
2023-06-30
0000811222
CDIF:ConvertibleNote371Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote371Member
2022-12-31
0000811222
CDIF:ConvertibleNote371Member
2023-06-30
0000811222
CDIF:ConvertibleNote372Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote372Member
2022-12-31
0000811222
CDIF:ConvertibleNote372Member
2023-06-30
0000811222
CDIF:ConvertibleNote373Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote373Member
2022-12-31
0000811222
CDIF:ConvertibleNote373Member
2023-06-30
0000811222
CDIF:ConvertibleNote38Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote38Member
2022-12-31
0000811222
CDIF:ConvertibleNote38Member
2023-06-30
0000811222
CDIF:ConvertibleNote39Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote39Member
2022-12-31
0000811222
CDIF:ConvertibleNote39Member
2023-06-30
0000811222
CDIF:ConvertibleNote401Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote401Member
2022-12-31
0000811222
CDIF:ConvertibleNote401Member
2023-06-30
0000811222
CDIF:ConvertibleNote402Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote402Member
2022-12-31
0000811222
CDIF:ConvertibleNote402Member
2023-06-30
0000811222
CDIF:ConvertibleNote403Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote403Member
2022-12-31
0000811222
CDIF:ConvertibleNote403Member
2023-06-30
0000811222
CDIF:ConvertibleNote404Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote404Member
2022-12-31
0000811222
CDIF:ConvertibleNote404Member
2023-06-30
0000811222
CDIF:ConvertibleNote405Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote405Member
2022-12-31
0000811222
CDIF:ConvertibleNote405Member
2023-06-30
0000811222
CDIF:ConvertibleNote406Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote406Member
2022-12-31
0000811222
CDIF:ConvertibleNote406Member
2023-06-30
0000811222
CDIF:ConvertibleNote407Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote407Member
2022-12-31
0000811222
CDIF:ConvertibleNote407Member
2023-06-30
0000811222
CDIF:ConvertibleNote408Member
2023-01-01
2023-06-30
0000811222
CDIF:ConvertibleNote408Member
2022-12-31
0000811222
CDIF:ConvertibleNote408Member
2023-06-30
0000811222
us-gaap:SeriesAPreferredStockMember
2023-06-30
0000811222
us-gaap:SeriesDPreferredStockMember
2023-06-30
0000811222
us-gaap:SeriesFPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesKPreferredStockMember
2023-06-30
0000811222
CDIF:SeriesNSeniorConvertiblePreferredStockMember
2023-01-01
2023-06-30
0000811222
CDIF:SeriesXPreferredStockMember
2023-01-01
2023-06-30
0000811222
us-gaap:SeriesCPreferredStockMember
2023-01-01
2023-06-30
0000811222
us-gaap:SeriesBPreferredStockMember
2023-05-24
2023-05-25
0000811222
us-gaap:SeriesDPreferredStockMember
2022-04-01
2022-06-30
0000811222
us-gaap:SeriesBPreferredStockMember
2022-04-01
2022-06-30
0000811222
us-gaap:ConvertibleNotesPayableMember
2023-01-01
2023-06-30
0000811222
us-gaap:WarrantMember
2022-12-31
0000811222
us-gaap:WarrantMember
2023-01-01
2023-06-30
0000811222
us-gaap:WarrantMember
2023-06-30
0000811222
us-gaap:SeriesFPreferredStockMember
CDIF:BuyBackAgreementMember
CDIF:AHIMember
2022-10-01
2022-10-31
0000811222
CDIF:AHIMember
2022-10-01
2022-10-31
0000811222
us-gaap:SegmentDiscontinuedOperationsMember
2023-04-01
2023-06-30
0000811222
us-gaap:SegmentDiscontinuedOperationsMember
2022-04-01
2022-06-30
0000811222
us-gaap:SegmentDiscontinuedOperationsMember
2023-01-01
2023-06-30
0000811222
us-gaap:SegmentDiscontinuedOperationsMember
2022-01-01
2022-06-30
0000811222
us-gaap:HealthCareMember
2022-12-31
0000811222
us-gaap:HealthCareMember
2023-01-01
2023-06-30
0000811222
us-gaap:HealthCareMember
2023-06-30
0000811222
srt:ChiefExecutiveOfficerMember
2023-06-30
0000811222
srt:ChiefExecutiveOfficerMember
2022-12-31
0000811222
srt:BoardOfDirectorsChairmanMember
2023-06-30
0000811222
srt:BoardOfDirectorsChairmanMember
2022-12-31
0000811222
2021-05-15
0000811222
srt:ChiefFinancialOfficerMember
2023-06-30
0000811222
srt:ChiefFinancialOfficerMember
2022-12-31
0000811222
CDIF:FirstDoctorMember
2021-05-02
2021-05-31
0000811222
CDIF:SecondDoctorMember
2021-05-02
2021-05-31
0000811222
CDIF:ThirdDoctorMember
2021-05-02
2021-05-31
0000811222
CDIF:YearEnd2022Member
2023-06-30
0000811222
CDIF:YearEnd2022Member
CDIF:SeriesJPreferredStockMember
2023-01-01
2023-06-30
0000811222
CDIF:YearEnd2022OneMember
2023-06-30
0000811222
CDIF:YearEnd2022OneMember
CDIF:SeriesJPreferredStockMember
2023-01-01
2023-06-30
0000811222
CDIF:YearEnd2023Member
2023-06-30
0000811222
CDIF:YearEnd2023Member
CDIF:SeriesJPreferredStockMember
2023-01-01
2023-06-30
0000811222
CDIF:YearEnd2024Member
2023-06-30
0000811222
CDIF:YearEnd2024Member
CDIF:SeriesJPreferredStockMember
2023-01-01
2023-06-30
0000811222
CDIF:YearEnd2025Member
2023-06-30
0000811222
CDIF:YearEnd2025Member
CDIF:SeriesJPreferredStockMember
2023-01-01
2023-06-30
0000811222
CDIF:FinancialServicesMember
2023-06-30
0000811222
CDIF:FinancialServicesMember
2022-12-31
0000811222
CDIF:HealthcareSegmentMember
2023-06-30
0000811222
CDIF:HealthcareSegmentMember
2022-12-31
0000811222
CDIF:RealEstatesMember
2023-06-30
0000811222
CDIF:RealEstatesMember
2022-12-31
0000811222
CDIF:OthersMember
2023-06-30
0000811222
CDIF:OthersMember
2022-12-31
0000811222
CDIF:FinancialServicesMember
2023-04-01
2023-06-30
0000811222
CDIF:FinancialServicesMember
2022-04-01
2022-06-30
0000811222
CDIF:HealthcareSegmentMember
2023-04-01
2023-06-30
0000811222
CDIF:HealthcareSegmentMember
2022-04-01
2022-06-30
0000811222
CDIF:RealEstatesMember
2023-04-01
2023-06-30
0000811222
CDIF:RealEstatesMember
2022-04-01
2022-06-30
0000811222
CDIF:SubsidiaryMember
2023-04-01
2023-06-30
0000811222
CDIF:SubsidiaryMember
2022-04-01
2022-06-30
0000811222
CDIF:CardiffLexingtonMember
2023-04-01
2023-06-30
0000811222
CDIF:CardiffLexingtonMember
2022-04-01
2022-06-30
0000811222
us-gaap:CorporateMember
2023-04-01
2023-06-30
0000811222
us-gaap:CorporateMember
2022-04-01
2022-06-30
0000811222
CDIF:FinancialServicesMember
2023-01-01
2023-06-30
0000811222
CDIF:FinancialServicesMember
2022-01-01
2022-06-30
0000811222
CDIF:HealthcareSegmentMember
2023-01-01
2023-06-30
0000811222
CDIF:HealthcareSegmentMember
2022-01-01
2022-06-30
0000811222
CDIF:RealEstatesMember
2023-01-01
2023-06-30
0000811222
CDIF:RealEstatesMember
2022-01-01
2022-06-30
0000811222
CDIF:SubsidiaryMember
2023-01-01
2023-06-30
0000811222
CDIF:SubsidiaryMember
2022-01-01
2022-06-30
0000811222
CDIF:CardiffLexingtonMember
2023-01-01
2023-06-30
0000811222
CDIF:CardiffLexingtonMember
2022-01-01
2022-06-30
0000811222
us-gaap:CorporateMember
2023-01-01
2023-06-30
0000811222
us-gaap:CorporateMember
2022-01-01
2022-06-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended: June 30, 2023
or
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ____________ to
_____________
Commission File Number: 000-49709
CARDIFF LEXINGTON CORPORATION |
(Exact name of registrant as specified in its charter) |
Nevada |
|
84-1044583 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
3753 Howard Hughes Parkway, Suite 200, Las Vegas, NV |
|
89169 |
(Address of principal executive offices) |
|
(Zip Code) |
844-628-2100 |
(Registrant’s telephone number, including area code) |
3200 Bel Air Drive, Las Vegas, NV 89109
|
(Former name, former address and former fiscal year, if changed since last report) |
Securities registered pursuant to Section 12(b)
of the Act: None
Securities
registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐ |
Accelerated filer ☐ |
Non-accelerated filer ☒ |
Smaller reporting company ☒ |
|
Emerging growth company ☐
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
☒
As of June 30, 2023, there were 943,475,613 shares of common stock
of the registrant issued and outstanding.
CARDIFF LEXINGTON CORPORATION
Quarterly Report on Form 10-Q
Period Ended June 30, 2023
TABLE OF CONTENTS
PART I
FINANCIAL INFORMATION
PART II
OTHER INFORMATION
PART I
FINANCIAL INFORMATION
| ITEM 1. | FINANCIAL STATEMENTS. |
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
CARDIFF
LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
AS OF
JUNE 30, 2023 AND DECEMBER 31, 2022
(UNAUDITED)
| |
| | | |
| | |
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash | |
$ | 411,209 | | |
$ | 226,802 | |
Accounts receivable-net | |
| 9,193,529 | | |
| 6,604,780 | |
Prepaid and other current assets | |
| 5,000 | | |
| 5,000 | |
Total current assets | |
| 9,609,738 | | |
| 6,836,582 | |
| |
| | | |
| | |
Property and equipment, net | |
| 47,438 | | |
| 55,439 | |
Land | |
| 540,000 | | |
| 540,000 | |
Goodwill | |
| 5,666,608 | | |
| 5,666,608 | |
Right of use - assets | |
| 153,933 | | |
| 218,926 | |
Due from related party | |
| 4,979 | | |
| 4,979 | |
Other assets | |
| 30,823 | | |
| 30,823 | |
Total assets | |
$ | 16,053,519 | | |
$ | 13,353,357 | |
| |
| | | |
| | |
LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued expense | |
$ | 2,522,332 | | |
$ | 2,038,595 | |
Accrued expenses - related parties | |
| 4,084,557 | | |
| 3,750,557 | |
Accrued interest | |
| 590,144 | | |
| 350,267 | |
Right of use - liability | |
| 126,752 | | |
| 142,307 | |
Due to director & officer | |
| 123,192 | | |
| 123,192 | |
Notes payable | |
| 24,724 | | |
| 15,809 | |
Notes payable - related party | |
| 156,384 | | |
| 37,024 | |
Convertible notes payable, net of debt discounts of $100,347 and $46,797, respectively | |
| 3,868,068 | | |
| 3,515,752 | |
Total current liabilities | |
| 11,496,153 | | |
| 9,973,503 | |
| |
| | | |
| | |
Other liabilities | |
| | | |
| | |
Notes payable | |
| 144,594 | | |
| 139,789 | |
Operating lease liability – long term | |
| 32,205 | | |
| 84,871 | |
Total liabilities | |
| 11,672,952 | | |
| 10,198,163 | |
| |
| | | |
| | |
Mezzanine equity | |
| | | |
| | |
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 868,058shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 3,682,537 | | |
| 3,125,002 | |
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value $4.00, 375,000 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 1,615,068 | | |
| 1,500,000 | |
Total Mezzanine Equity | |
| 5,297,605 | | |
| 4,625,002 | |
| |
| | | |
| | |
Stockholders' equity (deficit) | |
| | | |
| | |
Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 2,134,478 and 2,131,328 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | |
| 8,537,912 | | |
| 8,525,313 | |
Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value $4.00, 122 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 488 | | |
| 488 | |
Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 150,750 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 603,000 | | |
| 603,000 | |
Series F-1 Preferred Stock - 800,000 shares authorized, $0.001 par value, stated value $4.00, 35,752 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 143,008 | | |
| 143,008 | |
Series I Preferred Stock - 500,000,000 shares authorized, $0.001 par value, 14,885,000 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 59,540,000 | | |
| 59,540,000 | |
Series J Preferred Stock - 10,000,000 shares authorized, $0.001 par value, stated value $4.00, 1,713,584 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 6,854,336 | | |
| 6,854,336 | |
Series L Preferred Stock - 100,000,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 1,277,972 | | |
| 1,277,972 | |
Series R Preferred Stock - 5,000 shares authorized, $0.001 par value, stated value of $1,200, 165 shares issued and outstanding at June 30, 2023 and December 31, 2022 | |
| 198,000 | | |
| 198,000 | |
Common Stock - 7,500,000,000 shares authorized, $0.001 par value; 943,475,613 and 789,796,735 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | |
| 943,475 | | |
| 824,793 | |
Additional paid-in capital | |
| (8,497,309 | ) | |
| (8,581,265 | ) |
Accumulated deficit | |
| (70,517,920 | ) | |
| (70,855,453 | ) |
Total stockholders' equity (deficit) | |
| (917,038 | ) | |
| (1,469,808 | ) |
Total liabilities, mezzanine equity and stockholders' equity | |
$ | 16,053,519 | | |
$ | 13,353,357 | |
The accompanying notes are an integral part of
these condensed consolidated financial statements
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30,
2023 AND 2022
(UNAUDITED)
| |
| | | |
| | | |
| | | |
| | |
| |
THREE MONTHS
ENDED JUNE 30, | | |
SIX MONTHS
ENDED JUNE 30, | |
| |
2023 | | |
2022
(Restated) | | |
2023 | | |
2022
(Restated) | |
REVENUE | |
| | |
| | |
| | |
| |
Financial Services | |
$ | 118,304 | | |
$ | 472,014 | | |
$ | 272,703 | | |
$ | 936,857 | |
Healthcare | |
| 3,364,506 | | |
| 2,619,218 | | |
| 6,070,905 | | |
| 5,051,525 | |
Total revenue | |
| 3,482,810 | | |
| 3,091,232 | | |
| 6,343,608 | | |
| 5,988,382 | |
| |
| | | |
| | | |
| | | |
| | |
COST OF SALES | |
| | | |
| | | |
| | | |
| | |
Financial Services | |
| 21,297 | | |
| 112,776 | | |
| 48,126 | | |
| 325,222 | |
Healthcare | |
| 1,081,689 | | |
| 983,842 | | |
| 2,037,983 | | |
| 1,887,624 | |
Total cost of sales | |
| 1,102,986 | | |
| 1,096,618 | | |
| 2,086,109 | | |
| 2,212,846 | |
| |
| | | |
| | | |
| | | |
| | |
GROSS PROFIT | |
| 2,379,824 | | |
| 1,994,614 | | |
| 4,257,499 | | |
| 3,775,536 | |
| |
| | | |
| | | |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| | |
Depreciation expense | |
| 3,365 | | |
| 5,783 | | |
| 8,000 | | |
| 11,566 | |
Selling, general and administrative | |
| 670,289 | | |
| 866,213 | | |
| 1,829,768 | | |
| 1,940,477 | |
Total operating expenses | |
| 673,654 | | |
| 871,996 | | |
| 1,837,768 | | |
| 1,952,043 | |
| |
| | | |
| | | |
| | | |
| | |
INCOME FROM OPERATIONS | |
| 1,706,170 | | |
| 1,122,618 | | |
| 2,419,731 | | |
| 1,823,493 | |
| |
| | | |
| | | |
| | | |
| | |
OTHER INCOME (EXPENSE) | |
| | | |
| | | |
| | | |
| | |
Other income | |
| – | | |
| 8 | | |
| 205 | | |
| 8 | |
Gain on forgiveness of debt | |
| – | | |
| – | | |
| 390 | | |
| – | |
Interest expense and finance charge | |
| (844,459 | ) | |
| (1,035,811 | ) | |
| (1,539,623 | ) | |
| (3,255,987 | ) |
Conversion cost penalty and reimbursement | |
| – | | |
| – | | |
| (2,000 | ) | |
| – | |
Penalties and fees | |
| (15,000 | ) | |
| – | | |
| (30,000 | ) | |
| – | |
Amortization of debt discounts | |
| (30,633 | ) | |
| (111,706 | ) | |
| (48,616 | ) | |
| (156,252 | ) |
Total other income (expenses) | |
| (890,092 | ) | |
| (1,147,509 | ) | |
| (1,619,644 | ) | |
| (3,412,231 | ) |
| |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
LOSS FROM DISCONTINUED OPERATIONS | |
| – | | |
| (36,935 | ) | |
| – | | |
| (35,542 | ) |
| |
| | | |
| | | |
| | | |
| | |
NET INCOME (LOSS) FOR THE PERIOD | |
$ | 816,078 | | |
$ | (61,826 | ) | |
$ | 800,087 | | |
$ | (1,624,280 | ) |
DEEMED DIVIDENDS ON PREFERRED STOCK | |
| (125,744 | ) | |
| – | | |
| (462,555 | ) | |
| – | |
NET INCOME (LOSS)
ATTRIBUTABLE TO COMMON SHAREHOLDERS | |
$ | 690,334 | | |
$ | (61,826 | ) | |
$ | 337,532 | | |
$ | (1,624,280 | ) |
| |
| | | |
| | | |
| | | |
| | |
BASIC INCOME (LOSS) PER SHARE | |
| | | |
| | | |
| | | |
| | |
Continuing operations | |
$ | 0.00 | | |
| (0.00 | ) | |
| 0.00 | | |
| (0.01 | ) |
Discontinued operations | |
$ | 0.00 | | |
| (0.00 | ) | |
| 0.00 | | |
| (0.00 | ) |
| |
| | | |
| | | |
| | | |
| | |
DILUTED INCOME (LOSS) PER SHARE | |
| | | |
| | | |
| | | |
| | |
Continuing operations | |
$ | 0.00 | | |
| (0.00 | ) | |
| 0.00 | | |
| (0.00 | ) |
Discontinued operations | |
$ | 0.00 | | |
| (0.00 | ) | |
| 0.00 | | |
| (0.00 | ) |
| |
| | | |
| | | |
| | | |
| | |
BASIC WEIGHTED AVERAGE NUMBER OF COMMON SHARES – CONTINUED AND DISCONTINUED OPERATIONS | |
| 930,254,713 | | |
| 166,130,069 | | |
| 901,781,592 | | |
| 166,130,069 | |
DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES – CONTINUED AND DISCONTINUED OPERATIONS | |
| 14,435,802,103 | | |
| 166,130,069 | | |
| 17,836,079,282 | | |
| 166,130,069 | |
The accompanying notes are an integral part of
these condensed consolidated financial statements
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’
EQUITY (DEFICIENCY)
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Preferred
Stock Series A,
K and I | | |
Preferred
Stock Series B,
D, E, F, F-1, G, H, L | | |
Preferred
Stock Series
C and R | | |
Treasury Stock | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | |
Balance December 31, 2021 (Restated) | |
| 23,085,563 | | |
$ | 59,548,201 | | |
| 3,595,952 | | |
$ | 14,383,808 | | |
| 287 | | |
$ | 198,488 | | |
| (619,345 | ) | |
$ | (4,967,686 | ) |
Distribution of dividend | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| | | |
| | | |
| – | |
Net loss | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | |
Balance, June 30, 2022 (Restated) | |
| 23,085,563 | | |
$ | 59,548,201 | | |
| 3,595,952 | | |
$ | 14,383,808 | | |
| 287 | | |
$ | 198,488 | | |
| (619,345 | ) | |
$ | (4,967,686 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance December 31, 2022 | |
| 14,885,001 | | |
$ | 59,540,000 | | |
| 4,350,907 | | |
$ | 17,403,628 | | |
| 287 | | |
$ | 198,488 | | |
| – | | |
| – | |
Conversion of convertible notes payable | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | |
Distribution of dividend | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | |
Issuance of preferred stock series B | |
| – | | |
| – | | |
| 3,150 | | |
| 12,600 | | |
| – | | |
| – | | |
| – | | |
| – | |
Net income | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | |
Balance, June 30, 2023 | |
| 14,885,001 | | |
$ | 59,540,000 | | |
| 4,354,057 | | |
$ | 17,416,228 | | |
| 287 | | |
$ | 198,488 | | |
| – | | |
$ | – | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Common Stock | | |
Additional Paid-in | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balance December 31, 2021 (Restated) | |
| 166,130,069 | | |
$ | 167,421 | | |
$ | (3,479,126 | ) | |
$ | (65,118,744 | ) | |
$ | 732,361 | |
Distribution of dividend | |
| – | | |
| – | | |
| – | | |
| (100,476 | ) | |
| (100,476 | ) |
Net loss | |
| – | | |
| – | | |
| – | | |
| (1,624,280 | ) | |
| (1,624,280 | ) |
Balance, June 30, 2022 (Restated) | |
| 166,130,069 | | |
$ | 167,421 | | |
$ | (3,479,126 | ) | |
$ | (66,843,500 | ) | |
$ | (992,395 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance December 31, 2022 | |
| 824,793,235 | | |
$ | 824,793 | | |
$ | (8,581,264 | ) | |
$ | (70,855,453 | ) | |
$ | (1,469,808 | ) |
Conversion of convertible notes payable | |
| 118,682,378 | | |
| 118,682 | | |
| 71,555 | | |
| – | | |
| 190,237 | |
Accrued dividend | |
| – | | |
| – | | |
| – | | |
| (462,554 | ) | |
| (462,554 | ) |
Issuance of preferred stock series B | |
| – | | |
| – | | |
| 12,400 | | |
| – | | |
| 25,000 | |
Net income | |
| – | | |
| – | | |
| – | | |
| 800,087 | | |
| 800,087 | |
Balance, June 30, 2023 | |
| 943,475,613 | | |
$ | 943,475 | | |
$ | (8,497,308 | ) | |
$ | (70,517,920 | ) | |
$ | (917,038 | ) |
The accompanying notes are an integral part of
these condensed consolidated financial statements
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF
CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| |
| | | |
| | |
| |
Six Months Ended June 30, | |
| |
2023 | | |
2022 (Restated) | |
CASH FLOWS FROM OPERATING ACTIVITIES | |
| | | |
| | |
Net income (loss) for the period | |
$ | 800,087 | | |
$ | (1,624,280 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation | |
| 8,000 | | |
| 21,628 | |
Amortization of loan discount | |
| 48,616 | | |
| 156,252 | |
Gain on forgiveness of debt | |
| (390 | ) | |
| – | |
Other noncash items, net | |
| – | | |
| (28,271 | ) |
Bad debt | |
| 270,000 | | |
| – | |
Fair value settled upon conversion | |
| 123,566 | | |
| – | |
Conversion and note issuance cost | |
| 7,000 | | |
| – | |
Share issuance for service rendered | |
| 25,000 | | |
| – | |
Increase (decrease) in: | |
| | | |
| | |
Accounts receivable | |
| (2,858,749 | ) | |
| (192,425 | ) |
Right of use – assets | |
| 64,993 | | |
| (38,823 | ) |
Prepaid expenses and other current assets | |
| – | | |
| 8,000 | |
Increase (decrease) in: | |
| | | |
| | |
Accounts payable and accrued expense | |
| 693,788 | | |
| 699,107 | |
Accrued officer’s compensation | |
| 334,000 | | |
| 240,000 | |
Due from related parties | |
| – | | |
| 3,988 | |
Accrued interest | |
| 248,137 | | |
| 252,634 | |
Right of use – liabilities | |
| (68,221 | ) | |
| 29,015 | ) |
Net cash used in operating activities - continuing operations | |
| (304,173 | ) | |
| (473,175 | ) |
| |
| | | |
| | |
Net cash provided by operating activities - discontinued operations | |
| – | | |
| 35,542 | |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES | |
| | | |
| | |
Proceeds from convertible notes payable | |
| 355,500 | | |
| 555,730 | |
Repayment of convertible notes payable | |
| – | | |
| (5,908 | ) |
Payment of SBA loan | |
| – | | |
| (1,520 | ) |
Dividend on preferred stock | |
| – | | |
| (100,477 | ) |
Proceeds from line of credit | |
| 43,880 | | |
| – | |
Repayment of line of credit | |
| (30,160 | ) | |
| – | |
Payment of notes payable related party | |
| (5,336 | ) | |
| (5,065 | ) |
Proceeds from notes payable related party | |
| 124,696 | | |
| 7,948 | |
Net cash provided by financing activities | |
| 488,580 | | |
| 450,708 | |
| |
| | | |
| | |
NET INCREASE IN CASH | |
| 184,407 | | |
| 13,075 | |
CASH, BEGINNING OF PERIOD | |
| 226,802 | | |
| 595,987 | |
CASH, END OF PERIOD | |
$ | 411,209 | | |
$ | 609,062 | |
| |
| | | |
| | |
SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION | |
| | | |
| | |
Cash paid during the period for interest | |
$ | 2,044 | | |
$ | 46,098 | |
| |
| | | |
| | |
NON-CASH INVESTING AND FINANCING ACTIVITIES: | |
| | | |
| | |
Common stock issued upon conversion of notes payable and accrued interest | |
$ | 66,673 | | |
$ | – | |
Proceeds from related party | |
$ | – | | |
$ | 3,987 | |
The accompanying notes are an integral part of
these condensed consolidated financial statements
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| 1. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Organization and Nature of Operations
Cardiff Lexington Corporation (“Cardiff”)
was originally incorporated on September 3, 1986 in Colorado as Cardiff International Inc. On November 10, 2005, Cardiff merged with Legacy
Card Company, LLC and changed its name to Cardiff Lexington Corporation. On August 27, 2014, Cardiff redomiciled and became a corporation
under the laws of Florida. On April 13, 2021, Cardiff redomiciled and became a corporation under the laws of Nevada.
Cardiff is an acquisition holding company focused
on locating undervalued and undercapitalized companies, primarily in the healthcare industry, and providing them capitalization and leadership
to maximize the value and potential of their private enterprises while also providing diversification and risk mitigation for stockholders.
All of Cardiff’s operations are conducted through, and its income derived from, its various subsidiaries, which includes:
| · | We Three, LLC dba Affordable Housing Initiative
(“AHI”), which was acquired on May 15, 2014 and sold on October 31, 2022; |
| · | Edge View Properties, Inc. (“Edge View”),
which was acquired on July 16, 2014; |
| · | Platinum Tax Defenders (“Platinum Tax”),
which was acquired on July 31, 2018; and |
| · | Nova Ortho and Spine, PLLC (“Nova”), which was acquired on May 31, 2021. |
Princsiples of Consolidation
The condensed consolidated financial statements
include the accounts of Cardiff and its wholly owned subsidiaries AHI, Edge View, Platinum Tax and Nova (collectively, the “Company”).
AHI is included in discontinued operations. All significant intercompany accounts and transactions are eliminated in consolidation. Certain
prior period amounts may have been reclassified for consistency with the current period presentation. These reclassifications would have
no material effect on the reported condensed consolidated financial results.
Use of Estimates
The preparation of financial statements in conformity
with United States generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions
that affect certain reported amounts and disclosures. Management uses its historical records and knowledge of its business in making estimates.
Accordingly, actual results could differ from those estimates.
Accounts Receivable
Accounts receivable is reported on the
balance sheet at the net amounts expected to be collected by the Company. Management closely monitors outstanding accounts
receivable and charges off to expense any balances that are determined to be uncollectible, which was $270,000
and $0
as of June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company had net accounts
receivable of $9,193,529
and $6,604,780, respectively. Accounts receivables are primarily generated from subsidiaries in their normal course of business.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Property and Equipment
Property and equipment are carried at cost. Expenditures
for renewals and betterments that extend the useful lives of property, equipment or leasehold improvements are capitalized. Expenditures
for maintenance and repairs are charged to expense as incurred. Depreciation is calculated using the straight-line method for financial
reporting purposes based on the following estimated useful lives:
Schedule of estimated useful lives |
|
Classification |
Useful Life |
Equipment, furniture, and fixtures |
5 - 7 years |
Medical equipment |
10 years |
Leasehold improvements |
10 years or lease term, if shorter |
Goodwill and Other Intangible Assets
Goodwill and indefinite-lived brands are not amortized
but are evaluated for impairment annually or when indicators of a potential impairment are present. The Company’s impairment testing
of goodwill is performed separately from its impairment testing of indefinite-lived intangibles. The annual evaluation for impairment
of goodwill and indefinite-lived intangibles is based on valuation models that incorporate assumptions and internal projections of expected
future cash flows and operating plans. The Company believes such assumptions are also comparable to those that would be used by other
marketplace participants. During the six months ended June 30, 2023 and 2022, the Company did not recognize any goodwill impairment. The
Company based this decision on impairment testing of the underlying assets, expected cash flows, decreased asset value and other factors.
Valuation of Long-lived Assets
In accordance with the provisions of Accounting
Standards Codification (“ASC”) Topic 360-10-5, “Impairment or Disposal of Long-Lived Assets”, all long-lived
assets such as plant and equipment and construction in progress held and used by the Company are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held
and used is evaluated by a comparison of the carrying amount of assets to estimated discounted net cash flows expected to be generated
by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amounts of the assets exceed the fair value of the assets.
Revenue Recognition
The Company applies the following five-step model
to determine revenue recognition:
| · | Identification of a contract with a customer |
| · | Identification of the performance obligations
in the contact |
| · | Determination of the transaction price |
| · | Allocation of the transaction price to the separate
performance allocation |
| · | Recognition of revenue when performance obligations are satisfied. |
The Company only applies the five-step model when
it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers
to the customer. At contract inception and once the contract is determined to be within the scope of ASC 606, the Company assesses services
promised within each contract and determines those that are performance obligations and assesses whether each promised service is distinct.
The Company’s financial services sector
reports revenues as services are performed and its healthcare sector reports revenues at the time control of the services transfer to
the customer and from providing licensed and/or certified orthopedic procedures. The Company’s healthcare subsidiary does not have
contract liabilities or deferred revenue as there are no amounts prepaid for services.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Healthcare Income
Established billing rates are not the same as
actual amounts recovered for the Company’s healthcare subsidiary. They generally do not reflect what the Company is ultimately
paid and therefore are not reported in the condensed consolidated financial statements. The Company is typically paid amounts
based on established charges per procedure with guidance from the annually updated Current Procedural Terminology (“CPT”)
guidelines (a code set maintained by the American Medical Association through the CPT Editorial Panel), that designates relative value
units (“RVU's”) and a suggested range of charges for each procedure which is then assigned a CPT code.
This fee is discounted to reflect the percentage
paid to the Company “using a modifier” recognized by each insurance carrier for services, less deductible, co-pay, and contractual
adjustments which are deducted from the calculated fee. The net revenue is recorded at the time the services are rendered.
Contract Fees (Non-PIP)
The Company has contract fees for amounts earned
from its Non-Personal Injury Protection (“PIP”) related procedures, typically car accidents, and are collected on a contingency
basis. These cases are sold to a factor, who bears the risk of economic benefit or loss. After selling patient cases to the factor, any
additional funds collected by the Company are remitted to the factor.
Service Fees – Net (PIP)
The Company generates services fees from performing
various procedures on the date the services are performed. These services primarily include slip and falls as well as smaller nominal
Non-PIP services. Fees are collected primarily from third party insurance providers. These revenues are based on established insurance
billing rates less allowances for contractual adjustments and uncollectible amounts. These contractual adjustments vary by insurance company
and self-pay patients. The Company computes these contractual adjustments and collection allowances based on its historical collection
experience.
Completing the paperwork for each case and preparing
it for billing takes approximately ten business days after a procedure is performed. The majority of claims are then filed electronically
except for those remaining insurance carriers requiring paper filing. An initial response is usually received within four weeks from electronic
filing and up to six weeks from paper filing. Responses may be a payment, a denial, or a request for additional information.
The Company’s healthcare revenues are generated
from professional medical billings including facility and anesthesia services. With respect to facility and anesthesia services, the Company
is the primary obligor as the facility and anesthesia services are considered part of one integrated performance obligation. Historically
the Company receives 49.9% of collections from total gross billed. Accordingly, the Company recognized net healthcare service revenue
as 49.9% of gross billed amounts. Historical collection rates are estimated using the most current prior 12-month historical payment and
collection percentages.
The Company’s healthcare subsidiary has
contractual medical receivable sales and purchase agreements with third party factors which result in approximately 51% to 56% reduction
from the accounts receivables amounts when a receivable is sold to the factors. The Company evaluated the factored adjustments considering
the actual factored amounts per patient quarterly, and the reductions from accounts receivable that are factored were recorded in finance
charges as other expenses on the consolidated statement of operations.
The Company’s contracts for both its contract
and service fees each contain a single performance obligation (providing orthopedic services), as the promise to transfer the individual
services is not separately identifiable from other promises in the contracts and, therefore, not distinct, as a result, the entire transaction
price is allocated to this single performance obligation.
Accordingly, the Company recognizes revenues (net)
when the patient receives orthopedic care services. The Company’s patient service contracts generally have performance obligations
which are satisfied at a point in time. The performance obligation is for onsite or off-site care provided. Patient service contracts
are generally fixed-price, and the transaction price is in the contract. Revenue is recognized when obligations under the terms of the
contract with our patients are satisfied; generally, at the time of patient care.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Financial Services Income
The Company generates revenue from providing tax
resolution services to individuals and business owners that have federal and state tax liabilities by assisting its clients to settle
outstanding tax debts. Additionally, services include back taxes, offer in compromise, audit representation, amending tax returns, tax
preparation, wage garnishment relief, removal of bank levies and liens, and other financial challenges. The Company recognizes revenues
for these services as services are performed.
Advertising Costs
Advertising costs are expensed as incurred. Advertising
costs are included as a component of cost of sales in the condensed consolidated statements of operations and changes in stockholders’
equity. The Company recognized advertising and marketing expense of $133,326 and $82,269 for the three months ended June 30, 2023 and
2022, respectively. The Company recognized advertising and marketing expense of $171,679 and $210,054 for the six months ended June 30,
2023 and 2022, respectively.
Fair Value Measurements
Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level
of judgment associated with the inputs used to measure their fair value. The fair value hierarchy distinguishes between (1) market participant
assumptions developed based on market data obtained from independent sources (observable inputs), and (2) an entity’s own assumptions
about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The
fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value
hierarchy are described below:
| Level 1 | Inputs are unadjusted, quoted prices for identical assets or liabilities
in active markets at the measurement date. |
| Level 2 | Inputs, other than quoted prices included in Level 1, which are
observable for the asset or liability through corroboration with market data at the measurement date. |
| Level 3 | Unobservable inputs that reflect management's best estimate of
what market participants would use in pricing the asset or liability at the measurement date. |
Distinguishing Liabilities from Equity
The Company accounts for its series N senior convertible
preferred stock and series X senior convertible preferred stock subject to possible redemption in accordance with ASC 480, “Distinguishing
Liabilities from Equity”. Conditionally redeemable preferred shares are classified as temporary equity within the Company’s
condensed consolidated balance sheet.
Stock-Based Compensation
The Company accounts for its stock-based compensation
in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of
the fair value recognition provisions of section 718-10-30 of the FASB ASC. Pursuant to paragraph 718-10-30-6 of the FASB ASC, all transactions
in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value
of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
The measurement date used to determine the fair
value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable
that performance will occur.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Generally, all forms of share-based payments,
including stock option grants, warrants and restricted stock grants and stock appreciation rights are measured at their fair value on
the awards’ grant date, based on estimated number of awards that are ultimately expected to vest.
The expense resulting from share-based payments
is recorded in general and administrative expense in the condensed consolidated statements of operations.
Equity Instruments Issued to Parties Other
Than Employees for Acquiring Goods or Services
FASB ASU No 2018-07 prescribes equity instruments
issued to parties other than employees.
Income Taxes
Income taxes are determined in accordance with
ASC Topic 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their
respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income
in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities
of a change in tax rates is recognized in income in the period that includes the enactment date.
ASC 740 prescribes a comprehensive model for how
companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to
be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely
than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be
measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the
tax authority assuming full knowledge of the position and relevant facts.
As of June 30, 2023 and December 31, 2022, the
Company did not have any interest and penalties associated with tax positions and did not have any significant unrecognized uncertain
tax positions.
Income (Loss) per Share
FASB ASC Subtopic 260, Earnings Per Share,
provides for the calculation of “Basic” and “Diluted” earnings per share. Basic earnings per common share is computed
by dividing income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.
Diluted earnings per common share is computed by dividing income available to common stockholders by the weighted-average number of shares
of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been
outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding stock options,
warrants, and debts convertible into common stock. The dilutive effect of stock options and warrants are reflected in diluted earnings
per common share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of
the Company’s common stock can result in a greater dilutive effect from potentially dilutive securities. The diluted effect of debt
convertibles is reflected utilizing the if converted method.
Going Concern
The accompanying condensed consolidated financial
statements have been prepared using the going concern basis of accounting, which contemplates continuity of operations, realization of
assets and liabilities and commitments in the normal course of business. The Company has negative working capital and an accumulated deficit.
These factors raise substantial doubts about the Company’s ability to continue as a going concern. As of June 30, 2023, the Company
has an accumulated working capital deficit of approximately $1.9 million. The accompanying condensed consolidated financial statements
do not reflect any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications
of liabilities that might result if the Company is unable to continue as a going concern.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
The ability of the Company to continue as a going
concern and the appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusions. Management
has prospective investors and believes the raising of capital will allow the Company to fund its cash flow shortfalls and pursue new acquisitions.
There can be no assurance that the Company will be able to obtain sufficient capital from debt or equity transactions or from operations
in the necessary time frame or on terms acceptable to it. Should the Company be unable to raise sufficient funds, it may be required to
curtail its operating plans. In addition, increases in expenses may require cost reductions. No assurance can be given that the Company
will be able to operate profitably on a consistent basis, or at all, in the future. Should the Company not be able to raise sufficient
funds, it may cause cessation of operations.
Recent Accounting Standards
Changes to accounting principles are established
by the FASB in the form of Accounting Standards Update (“ASU”) to the FASB's Codification. The Company considers the applicability
and impact of all ASU's on its financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof.
In June 2016, the FASB issued ASU No. 2016-13,
Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses
when it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses
on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition
of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued
ASU No. 2019-10, Financial Instruments -- Credit Losses (Topic 326), Derivatives and hedging (Topic 815) and Leases (Topic 842),
which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The Company
has adopted this standard effective January 1, 2023, and it resulted in the Company recognizing an allowance for doubtful accounts of
$270,000 during the six months ended June 30, 2023.
Management does not believe that any other recently
issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements.
As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.
2. |
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS |
Subsequent to the initial issuance of the Company's
2021 financial statements on June 30, 2022, management reconsidered the methodology previously applied in its valuation of goodwill and
redeemable preferred stocks.
The Company agreed to issue 818,750 additional
shares of series J Preferred Stock with an aggregate stated value equal to $3,275,000 if, as of May 31, 2022, Nova’s trailing twelve
months minimum pre-tax net income exceeded $1,979,320 (the “Milestone”). The Company finalized its purchase price accounting
and allocation in 2022 and recorded purchase consideration of $6,100,000 associated with the cash consideration, the fair value of the
series J preferred stock and the fair value of the contingent consideration. The impact of the correction is reflected in $3,275,000 increase
to goodwill and contingent consideration liability on the consolidated balance sheet.
In December 2022, the Company identified an error in its classification
for its series N senior convertible preferred stock for the acquisition of NOVA as presented in its audited balance sheet as of December
31, 2021. Pursuant to ASC 250, “Accounting changes and error corrections” issued by FASB and SAB 99 “Materiality”
issued by SEC, the Company determined the impact of the error was immaterial. The impact of the error correction is reflected in $3,125,002
increase to the mezzanine equity and offsetting decrease to the Series N Preferred Stock in subject to possible redemption mezzanine equity
line item.
The Company and We3 managers entered into a resignation,
release and buyback agreement and addendum, effective October 31, 2022. The Company presented in prior periods operating loss as loss
from discontinued operations in the amount of $1,920 on the consolidated statement of operations for the six months ended June 30, 2022.
The Company identified that NOVA’s accounts
receivable as presented in its balance sheet as of December 31, 2021, was understated due to an error in the collection utilized to estimate
NOVA’s accounts receivable. The impact of this correction on the accounting estimates is reflected in $1,076,000 decrease to accounts
receivable as of June 30, 2022 and $1,076,000 increase in finance charges for the six months ended June 30, 2022.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
The following table summarizes the impacts of
the error corrections on the Company's financial statements for each of the periods presented below:
i. Balance sheet
Schedule of restated financial information | |
| | | |
| | | |
| | |
| |
Impact of correction of error | |
June 30, 2022 (Unaudited) | |
As previously reported | | |
Adjustments | | |
As restated | |
| |
| | |
| | |
| |
Total assets | |
$ | 12,464,017 | | |
$ | 3,275,000 | | |
$ | 15,739,017 | |
| |
| | | |
| | | |
| | |
Total liabilities | |
| 10,331,410 | | |
| 3,275,000 | | |
| 13,606,410 | |
| |
| | | |
| | | |
| | |
Mezzanine equity | |
| – | | |
| 3,125,002 | | |
| 3,125,002 | |
| |
| | | |
| | | |
| | |
Total shareholders' equity | |
$ | 2,132,607 | | |
$ | (3,125,002 | ) | |
$ | (992,395 | ) |
ii. Statement of operations
| |
Impact of correction of error | |
Three months ended June 30, 2022 (Unaudited) | |
As previously reported | | |
Adjustments | | |
As restated | |
| |
| | |
| | |
| |
Revenue | |
$ | 3,130,744 | | |
$ | (39,512 | ) | |
$ | 3,091,232 | |
Cost of sales | |
| 1,115,232 | | |
| (18,614 | ) | |
| 1,096,618 | |
Gross margin | |
| 2,015,512 | | |
| (20,898 | ) | |
| 1,994,614 | |
Operating expense | |
| 912,829 | | |
| (40,833 | ) | |
| 871,996 | |
Income from operations | |
$ | 1,102,683 | | |
$ | 19,935 | | |
$ | 1,122,618 | |
Other income (expense), net | |
| (1,147,509 | ) | |
| – | | |
| (1,147,509 | ) |
Net loss before discontinued operations | |
| ) | |
| | |
| ) |
Loss from discontinued operations | |
| (17,000 | ) | |
| (19,935 | ) | |
| (36,935 | ) |
Net loss | |
$ | (61,826 | ) | |
$ | – | | |
$ | (61,826 | ) |
Basic Loss per Share | |
| | | |
| | | |
| | |
Continued Operations | |
| (0.00 | ) | |
| | | |
| (0.00 | ) |
Discontinued Operations | |
| (0.00 | ) | |
| | | |
| (0.00 | ) |
Weighted Average Shares Outstanding - Basic Earnings Loss per Share | |
| | | |
| | | |
| | |
Continued Operations | |
| 166,130,069 | | |
| | | |
| 166,130,069 | |
Discontinued Operations | |
| 166,130,069 | | |
| | | |
| 166,130,069 | |
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| |
Impact of correction of error | |
Six months ended June 30, 2022 (Unaudited) | |
As previously reported | | |
Adjustments | | |
As restated | |
| |
| | |
| | |
| |
Revenue | |
$ | 6,071,738 | | |
$ | (83,356 | ) | |
$ | 5,988,382 | |
Cost of sales | |
| 2,250,934 | | |
| (38,088 | ) | |
| 2,212,846 | |
Gross margin | |
| 3,820,804 | | |
| (45,268 | ) | |
| 3,775,536 | |
Operating expense | |
| 1,994,757 | | |
| (42,714 | ) | |
| 1,952,043 | |
Income from operations | |
$ | 1,826,047 | | |
$ | (2,554 | ) | |
$ | 1,823,493 | |
Other income (expense), net | |
| (2,340,705 | ) | |
| (1,071,526 | ) | |
| (3,412,231 | ) |
Net loss before discontinued operations | |
| ) | |
| ) | |
| ) |
Loss from discontinued operations | |
| (33,622 | ) | |
| (1,920 | ) | |
| (35,542 | ) |
Net loss | |
$ | (548,280 | ) | |
$ | (1,076,000 | ) | |
$ | (1,624,280 | ) |
Basic Loss per Share | |
| | | |
| | | |
| | |
Continued Operations | |
| (0.00 | ) | |
| | | |
| (0.01 | ) |
Discontinued Operations | |
| (0.00 | ) | |
| | | |
| (0.01 | ) |
Weighted Average Shares Outstanding - Basic Earnings Loss per Share | |
| | | |
| | | |
| | |
Continued Operations | |
| 166,130,069 | | |
| | | |
| 166,130,069 | |
Discontinued Operations | |
| 166,130,069 | | |
| | | |
| 166,130,069 | |
| 3. | REVISION OF FINANCIAL STATEMENTS |
During the preparation of the financial statements
for the six months ended June 30, 2023, the Company found that the results of the settlement agreement with Red Rock Travel Group (“Red
Rock”) were incorrectly reflected on the consolidated statement of stockholders’ equity(deficiency) as of December 31, 2022.
The Company determined that these errors were immaterial to the previously issued consolidated financial statements, and as such no restatement
was necessary. The revisions discussed below were made to the December 31, 2022 balance sheet and statement of stockholders’ equity
(deficiency).
As a result of the settlement agreement with Red
Rock on July 29, 2022, the Company reduced 35,000,000 shares of common shares on the consolidated financial statements as of December
31, 2022. The certificate of the common stock for 35,000,000 shares which were originally issued on February 24, 2020 was returned as
part of the 2022 agreement with Red Rock and 3,500 common shares were cancelled which were equivalent to 35,000,000 shares before the
10,000:1 reverse split on May 12, 2020. Consequently, the December 31, 2022 financial statements as originally reported were understated
by 34,996,500 common shares. The impact of the correction is reflected in the $35,097 increase to common stock and decrease the same amount
to additional paid-in-capital on the consolidated statement of shareholders’ equity. The adjustment had no impact on earnings per
share for any 2022 period.
On July 31, 2018, the Company issued 8,200,562
shares of series K preferred stock to the prior owners of Red Rock for the consideration of the acquisition of Red Rock. The acquisition
was not completed, and Red Rock returned the 8,200,562 shares of series K preferred shares during the year ended December 31, 2018. A
total of 8,200,562 shares of series K Preferred Share were cancelled The impact of the correction is reflected in the $8,201 decrease
to series K Preferred Stock and increase the same amount to additional paid-in-capital on the consolidated statement of shareholders’
equity (deficiency).
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| 4. | ACCOUNTS PAYABLE AND ACCRUED EXPENSES |
Schedule of account payable and accrued expenses | |
| | | |
| | |
| |
June 30, 2023 | | |
December 31,
2022 | |
Accounts payable | |
$ | 437,718 | | |
$ | 342,330 | |
Accrued credit cards | |
| 15,358 | | |
| 45,722 | |
Accrued expense – previously factored liability | |
| 1,291,691 | | |
| 776,414 | |
Accrued income taxes, and other taxes | |
| 5,346 | | |
| 6,732 | |
Accrued professional fees | |
| 694,140 | | |
| 573,040 | |
Accrued advertising | |
| 69,656 | | |
| 69,656 | |
Accrued payroll | |
| 8,423 | | |
| 14,292 | |
Accrue expense - other | |
| – | | |
| 363 | |
Accrued expense - dividend payable | |
| – | | |
| 210,046 | |
Total | |
$ | 2,522,332 | | |
$ | 2,038,595 | |
The Company is delinquent paying certain income
and property taxes. As of June 30, 2023 and December 31, 2022, the balance for these taxes, penalties and interest is $5,346 and $6,732,
respectively.
| 5. | PLANT AND EQUIPMENT, NET |
Property and equipment as of June 30, 2023 and
December 31, 2022 is as follows:
Schedule of property and equipment | |
| | | |
| | |
| |
June 30, 2023 | | |
December 31, 2022 | |
Medical equipment | |
$ | 96,532 | | |
$ | 96,532 | |
Computer Equipment | |
| 9,189 | | |
| 9,189 | |
Furniture, fixtures and equipment | |
| 30,841 | | |
| 35,974 | |
Leasehold Improvement | |
| 15,950 | | |
| 15,950 | |
Total | |
| 152,512 | | |
| 157,645 | |
Less: accumulated depreciation | |
| (105,074 | ) | |
| (102,206 | ) |
Property and equipment, net | |
$ | 47,438 | | |
$ | 55,439 | |
For the three and six months ended June 30,
2023, total depreciation expense was $3,365
and $8,000,
respectively. For the three and six months ended June 30, 2022, total depreciation expense was $10,814
and $21,628,
respectively. Depreciation expense recorded as cost of sales for the three and six months ended June 30, 2022 was $5,031
and $10,062,
respectively.
As of June 30, 2023 and December 31, 2022, the
Company had 27 acres of land valued at approximately $540,000. The land is currently vacant and is expected to be developed into a residential
community.
At June 30, 2023 and December 31, 2022, the Company
had a revolving line of credit with a financial institution for $92,500 which was personally guaranteed by the manager of Platinum Tax.
The loan accrues interest at 11.70% at June 30, 2023 and 10.95% at December 31, 2022. As of June 30, 2023 and December 31, 2022, the Company
had $8,749 and $0, respectively, of outstanding balance against the line of credit.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| 8. | RELATED PARTY TRANSACTIONS |
From time to time, the previous owner who is currently
the manager of Platinum Tax loaned funds to Platinum Tax to cover short term operating needs. Amounts owed as of June 30, 2023 and December
31, 2022 were $156,384 and $37,024, respectively.
In connection with the acquisition of Edge View
on July 16, 2014, the Company assumed amounts due to previous owners who are current managers Edge View. These amounts are due on demand
and do not bear interest. The balance of these amounts are $4,979 as of June 30, 2023 and December 31, 2022.
The Company obtained short-term advances from
the Chairman of the Board that are non-interest bearing and due on demand. As of June 30, 2023 and December 31, 2022, the Company owed
the Chairman $123,192 and $123,192, respectively.
See also Note 14 for compensation paid to employees
of the Company.
| 9. | NOTES AND LOANS PAYABLE |
Notes payable at June 30, 2023 and December 31,
2022, respectively, are summarized as follows:
Schedule of notes payable | |
| | |
| |
| |
June 30, 2023 | | |
December 31, 2022 | |
Notes and loans payable | |
$ | 169,318 | | |
$ | 155,598 | |
Less current portion | |
| (24,724 | ) | |
| (15,809 | ) |
Long-term portion | |
$ | 144,594 | | |
$ | 139,789 | |
Long-term debt matures as follows:
Schedule of maturities of long-term debt | |
| |
| |
Amount | |
2024 | |
$ | 24,724 | |
2025 | |
| 4,986 | |
2026 | |
| 4,986 | |
2027 | |
| 4,986 | |
2028 | |
| 4,986 | |
Thereafter | |
| 124,650 | |
Total | |
$ | 169,318 | |
Loans and Notes Payable – Unrelated Party
On March 12, 2009, the Company issued a debenture
in the principal amount of $20,000. The debenture bears interest at 12% per annum and matured on September 12, 2009. The balance of the
debenture was $10,989 at June 30, 2023 and December 31, 2022 and the accrued interest was $6,882 and $6,229 at June 30, 2023 and December
31, 2022, respectively. The Company assigned all of its receivables from consumer activations of the rewards program as collateral on
this debenture.
Small Business Administration (“SBA”)
Loans
On June 2, 2020, the Company obtained an SBA loan
in the principal amount of $150,000 with an interest rate of 3.75% and a maturity date of June 2, 2050. The Company reclassified $5,723
of accrued interest to the principal amounts for the six months ended June 30, 2023. The principal balance and accrued interest at June
30, 2023 was $149,580 and $0, respectively, and principal and accrued interest at December 31, 2022 was $144,609 and $5,723, respectively.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| 10. | CONVERTIBLE NOTES PAYABLE |
As of June 30, 2023 and December 31, 2022, the
Company had convertible debt outstanding net of amortized debt discount of $3,868,068 and $3,515,752, respectively. During the six months
ended June 30, 2023, the Company received net proceeds of $355,500 from convertible notes. During the six months ended June 30, 2022,
the Company had proceeds of $752,260 from convertible notes and repaid $5,908 to convertible noteholders. There are debt discounts
associated with the convertible debt of $100,347 and $46,798 at June 30, 2023 and December 31, 2022, respectively. For the six months
ending June 30, 2023 and 2022, the Company recorded amortization of debt discounts of $ 48,616 and $156,252, respectively. For the three
months ending June 30, 2023 and 2022, the Company recorded amortization of debt discounts of $30,633 and $111,706, respectively. During
the six months ended June 30, 2023, the Company converted $58,800 of convertible debt, $5,873 in accrued interest and $2,000 in penalties
and fees into 118,682,378 shares of the Company’s common stock. The Company recognized $123,566 of interest expense and additional
paid-in capital to adjust fair value for the debt settlement during the six months ended June 30, 2023. The Company had no convertible
debt conversions during the six months ended June 30, 2022.
On September 22, 2022, the Company entered into
a security exchange and purchase agreement with its largest lender to consolidate all promissory notes held by it and related accrued
interest in exchange for (1) one consolidated senior secured convertible promissory note in the amount of $2,600,000 and (2) 375,000 shares
of series X senior convertible preferred stock totaling $1,500,000 with a par value of $0.001, stated value of $4.00, convertible into
common shares at a 1:1 conversion rate, non-dilutive and non-voting shares. Prior to conversion, all promissory notes with this lender
totaled to $4,791,099 consisting of principal of $3,840,448 and accrued interest of $950,651 resulting in a gain on debt consolidation
of $1,397,271.
Convertible notes as of June 30, 2023 and December
31, 2022 are summarized as follows:
Schedule of convertible notes summary | |
| | |
| |
| |
June 30, 2023 | | |
December 31, 2022 | |
Convertible notes payable | |
$ | 3,968,415 | | |
$ | 3,562,550 | |
Discounts on convertible notes payable | |
| (100,347 | ) | |
| (46,798 | ) |
Total convertible debt less debt discount | |
| 3,868,068 | | |
| 3,515,752 | |
Current portion | |
| 3,868,068 | | |
| 3,515,752 | |
Long-term portion | |
$ | – | | |
$ | – | |
The following is a schedule of convertible notes
payable as of and for the six months ended June 30, 2023.
Schedule of convertible
notes payable | | |
| |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Note # | | |
Issuance | |
Maturity | |
Principal Balance 12/31/22 | | |
New Loan | | |
Principal Conversions | | |
Shares Issued Upon Conversion | | |
Principal Balance 6/30/23 | | |
Accrued Interest on Convertible Debt at 12/31/22 | | |
Interest Expense On Convertible Debt For the Period
Ended 6/30/23 | | |
Accrued Interest on Convertible Debt at 6/30/23 | | |
Unamortized Debt Discount At 6/30/23 | |
7-1 | | |
10/28/2016 | |
10/28/2017 | |
| 10,000 | | |
$ | – | | |
$ | (10,000 | ) | |
| 23,405,455 | | |
$ | – | | |
$ | 2,263 | | |
$ | – | | |
$ | – | | |
$ | – | |
9 | | |
9/12/2016 | |
9/12/2017 | |
| 50,080 | | |
| – | | |
| – | | |
| – | | |
| 50,080 | | |
| 14,157 | | |
| 4,967 | | |
| 19,124 | | |
| – | |
10 | | |
1/24/2017 | |
1/24/2018 | |
| 55,000 | | |
| – | | |
| – | | |
| – | | |
| 55,000 | | |
| 69,876 | | |
| 5,455 | | |
| 75,331 | | |
| – | |
10-1 | | |
2/10/2023 | |
2/10/2024 | |
| – | | |
| 50,000 | | |
| – | | |
| – | | |
| 50,000 | | |
| – | | |
| 2,877 | | |
| 2,877 | | |
| – | |
10-2 | | |
3/30/2023 | |
3/30/2024 | |
| – | | |
| 25,000 | | |
| – | | |
| – | | |
| 25,000 | | |
| – | | |
| 945 | | |
| 945 | | |
| – | |
29-2 | | |
11/8/2019 | |
11/8/2020 | |
| 36,604 | | |
| – | | |
| – | | |
| – | | |
| 36,604 | | |
| 20,160 | | |
| 4,356 | | |
| 24,516 | | |
| – | |
31 | | |
8/28/2019 | |
8/28/2020 | |
| – | | |
| – | | |
| – | | |
| – | | |
| – | | |
| 8,385 | | |
| – | | |
| 8,385 | | |
| – | |
37-1 | | |
9/3/2020 | |
6/30/2021 | |
| 113,667 | | |
| – | | |
| – | | |
| – | | |
| 113,667 | | |
| 28,756 | | |
| 10,146 | | |
| 48,902 | | |
| – | |
37-2 | | |
11/2/2020 | |
8/31/2021 | |
| 113,167 | | |
| – | | |
| – | | |
| – | | |
| 113,167 | | |
| 27,510 | | |
| 10,101 | | |
| 47,611 | | |
| – | |
37-3 | | |
12/29/2020 | |
9/30/2021 | |
| 113,166 | | |
| – | | |
| – | | |
| – | | |
| 113,166 | | |
| 26,474 | | |
| 10,101 | | |
| 46,575 | | |
| – | |
38 | | |
2/9/2021 | |
2/9/2022 | |
| 96,000 | | |
| – | | |
| (48,800 | ) | |
| 85,276,923 | | |
| 47,200 | | |
| 27,939 | | |
| 5,910 | | |
| 33,849 | | |
| – | |
39 | | |
4/26/2021 | |
4/26/2022 | |
| 168,866 | | |
| – | | |
| – | | |
| – | | |
| 168,866 | | |
| 39,684 | | |
| 18,423 | | |
| 58,106 | | |
| – | |
40-1 | | |
9/22/2022 | |
9/22/23 | |
| 2,600,000 | | |
| – | | |
| – | | |
| 10,000,000 | | |
| 2,600,000 | | |
| 71,233 | | |
| 128,932 | | |
| 196,164 | | |
| – | |
40-2 | | |
11/4/2022 | |
11/4/2023 | |
| 68,666 | | |
| – | | |
| – | | |
| – | | |
| 68,666 | | |
| 1,072 | | |
| 3,405 | | |
| 4,477 | | |
| 5,973 | |
40-3 | | |
11/28/2022 | |
11/28/2023 | |
| 68,667 | | |
| – | | |
| – | | |
| – | | |
| 68,667 | | |
| 620 | | |
| 3,405 | | |
| 4,025 | | |
| 7,102 | |
40-4 | | |
12/21/2022 | |
12/21/2023 | |
| 68,667 | | |
| – | | |
| – | | |
| – | | |
| 68,667 | | |
| 187 | | |
| 3,405 | | |
| 3,592 | | |
| 8,184 | |
40-5 | | |
1/24/2023 | |
1/24/2024 | |
| – | | |
| 90,166 | | |
| – | | |
| – | | |
| 90,166 | | |
| – | | |
| 3,878 | | |
| 3,878 | | |
| 13,486 | |
40-6 | | |
3/21/2023 | |
3/21/2024 | |
| – | | |
| 139,166 | | |
| – | | |
| – | | |
| 139,166 | | |
| – | | |
| 3,851 | | |
| 3,851 | | |
| 26,520 | |
40-7 | | |
6/5/2023 | |
6/5/2024 | |
| – | | |
| 139,166 | | |
| – | | |
| – | | |
| 139,166 | | |
| – | | |
| 953 | | |
| 953 | | |
| 34,155 | |
40-8 | | |
6/13/2023 | |
6/13/2024 | |
| – | | |
| 21,167 | | |
| – | | |
| – | | |
| 21,167 | | |
| – | | |
| 99 | | |
| 99 | | |
| 4,927 | |
| | |
| |
| |
$ | 3,562,550 | | |
$ | 464,665 | | |
$ | (58,800 | ) | |
| 118,682,378 | | |
$ | 3,968,415 | | |
$ | 338,316 | | |
$ | 221,209 | | |
$ | 583,260 | | |
$ | 100,347 | |
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Note 7-1
On October 28, 2016, the Company issued a convertible
promissory note in the principal amount of $50,000, which matured on October 28, 2017. Note 7-1 is currently in default and accrues interest
at a default interest rate of 20% per annum.
Note 9
On September 12, 2016, the Company issued a convertible
promissory note in the principal amount of $80,000 for services rendered, which matured on September 12, 2017. Note 9 is currently in
default and accrues interest at a default interest rate of 20% per annum.
Notes 10, 10-1 and 10-2
On January 24, 2017, the Company issued a convertible
promissory note in the principal amount of $80,000 for services rendered, which matured on January 24, 2018. Note 10 is currently in default
and accrues interest at a default interest rate of 20% per annum. On February 10, 2023, the Company executed a second tranche under this
note in the principal amount of $50,000 (Note 10-1). On March 30, 2023, the Company executed a third tranche under this note in the principal
amount of $25,000 (Note 10-2). Notes 10-1 and 10-2 accrue interest at a rate of 15% per annum.
Notes 29, 29-1 and 29-2
On May 10, 2019, the Company issued a convertible
promissory note in the principal amount of $150,000. On November 8, 2019, this note (Note 29) was purchased by and assigned to an unrelated
party. The amount assigned was the existing principal amount of $150,000 and accrued interest of $5,918 which was issued as Note 29-1,
plus a new convertible promissory note in the principal amount of $62,367 which was issued as Note 29-2. Note 29-2 is currently in default
and accrues interest at a default interest rate of 24% per annum.
Note 31
On August 28, 2019, the Company issued a convertible
promissory note in the principal amount of $120,000, which matured on August 28, 2020. Note 31 is currently in default and accrues interest
at a default interest rate of 24% per annum.
Notes 37-1, 37-2 and 37-3
On September 3, 2020, the Company issued a convertible
promissory note in the principal amount of $200,000, with an original issue discount of $50,000, which could be drawn in several tranches.
On September 3, 2020, the Company executed the first tranche in the principal amount of $67,000, less an original issue discount of $17,000,
which matured on June 30, 2021 (Note 37-1). On November 2, 2020, the Company executed the second tranche in the principal amount of $66,500,
less an original issue discount of $16,500, which matured on August 31, 2021 (Note 37-2). On December 29, 2020, the Company executed the
third tranche in the principal amount of $66,500, less an original issue discount of $16,500, which matured on September 30, 2021 (Note
37-3). Notes 37-1, 37-2 and 27-3 are currently in default and accrue interest at a default interest rate of 18% per annum.
Note 38
On February 9, 2021, the Company issued a convertible
promissory note in the principal amount $103,500, which matured on February 9, 2022. Note 38 is currently in default and accrues interest
at a default interest rate of 22% per annum.
Note 39
On April 26, 2021, the Company issued a convertible
promissory note in the principal amount $153,500, which matured on May 10, 2022. Note 39 is currently in default and accrues interest
at a default interest rate of 22% per annum.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Notes 40-1, 40-2, 40-3, 40-4, 40-5, 40-6, 40-7 and 40-8
On September 22, 2022, the Company issued a
convertible promissory note in the principal amount of $2,600,000 in exchange for total of $4,791,099 of defaulted promissory notes
balances (Note 40-1). On November 4, 2022, the Company executed a second tranche under this note in the principal amount of $68,667,
less an original issue discount and fee of $18,667 (Note 40-2). On November 28, 2022, the Company executed the third tranche under
this note in the principal amount of $68,667, less an original issue discount and fee of $18,667 (Note 40-3). On November 28, 2022,
the Company executed a fourth tranche under this note in the principal amount of $68,667, less an original issue discount and fee of
$18,667 (Note 40-4). On January 24, 2023, the Company executed a fifth tranche under this note in the principal amount of $90,166,
less an original issue discount and fee of $25,166 (Note 40-5). On March 21, 2023, the Company executed a sixth tranche under this
note in the principal amount of $136,666, less an original issue discount and fee of $39,166 (Note 40-6). On June 5, 2023, the
Company executed a seventh tranche under this note in the principal amount of $136,667,
less original issue discount and fee of $39,167
(Note 40-7). On June 13, 2023, the Company executed a eighth tranche under this note in the principal amount of
$21,167,
less original issue discount and fee of $5,167
(Note 40-8). All of the Note 40 tranches mature in one year from the note issuance date and accrue interest at a rate of 10%
per annum.
Preferred Stock
The Company has designated multiple series of
preferred stock, including 4
shares of series A preferred stock, 3,000,000
shares of series B preferred stock, 500
shares of series C preferred stock, 800,000
shares of series D preferred stock, 1,000,000
shares of series E preferred stock, 800,000
shares of series F preferred stock, 800,000
shares of series F-1 preferred stock, 500,000,000
shares of series I preferred stock, 10,000,000
shares of series J preferred stock, 10,937,500 shares of series K preferred stock, 100,000,000 shares of series L preferred stock,
3,000,000 shares of series N senior convertible preferred stock, 5,000 shares of series R preferred stock and 5,000,000 shares of series
X senior convertible preferred stock.
The following is a description of the rights and
preferences of each series of preferred stock.
Redeemable Preferred Stock
The Company recognized the series N senior convertible
preferred stock and series X senior convertible preferred stock as mezzanine equity since the redeemable preferred stock may be redeemed
at the option of the holder, but is not mandatorily redeemable.
Series N Senior Convertible Preferred Stock
Ranking. The series N senior convertible
preferred stock ranks, with respect to the payment of dividends and the distribution of assets upon liquidation, (i) senior to all common
stock and each other class or series that is not expressly made senior to or on parity with the series N senior convertible preferred
stock; (ii) on parity with each class or series that is not expressly subordinated or made senior to the series N senior convertible preferred
stock; and (iii) junior to all indebtedness and other liabilities with respect to assets available to satisfy claims against the Company
and each class or series that is expressly made senior to the series N senior convertible preferred stock.
Dividend Rights. Holders of series N senior
convertible preferred stock are entitled to dividends at a rate per annum of 12.0% of the stated value ($4.00 per share); provided that
upon an event of default (as defined in the certificate of designation for the series N senior convertible preferred stock), such rate
shall increase by 8% per annum. Dividends shall accrue from day to day, whether or not declared, and shall be cumulative. Dividends shall
be payable quarterly in arrears on each dividend payment date in cash or common stock at the Company’s discretion. Dividends payable
in common stock shall be calculated based on a price equal to eighty percent (80%) of the volume weighted average price for the common
stock on the Company’s principal trading market (the “VWAP”) during the five (5) trading days immediately prior to the
applicable dividend payment date. At June 30, 2023, cumulative dividends on Series N Preferred Stock were $557,535.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Liquidation Rights. Subject to the rights
of creditors and the holders of any senior securities or parity securities (in each case, as defined in the certificate of designation),
upon any liquidation of the Company or its subsidiaries, before any payment or distribution of the assets of the Company (whether capital
or surplus) shall be made to or set apart for the holders of junior securities (as defined in the certificate of designation), including
the common stock, each holder of outstanding series N senior convertible preferred stock shall be entitled to receive an amount of cash
equal to 115% of the stated value of $4.00 per share, plus an amount of cash equal to all accumulated accrued and unpaid dividends thereon
(whether or not declared) to, but not including the date of final distribution to such holders.
Voting Rights. Holders of series N senior
convertible preferred stock do not have any voting rights; provided that, so long as any shares of series N senior convertible preferred
stock are outstanding, the affirmative vote of holders of a majority of the series N senior convertible preferred stock, which majority
must include SILAC Insurance Company so long as it holds any shares of series N senior convertible preferred stock, voting as a separate
class, shall be necessary for approving, effecting or validating any amendment, alteration or repeal of any of the provisions of the certificate
of designation or prior to the Company’s (or Nova’s) creation or issuance of any parity securities or new indebtedness (as
defined in the certificate of designation); provided that the foregoing shall not apply to any financing transaction the use of proceeds
of which will be used to redeem the series N senior convertible preferred stock and the warrants issued in connection therewith. In addition,
the affirmative vote of holders of 66% of the series N senior convertible preferred stock, voting as a separate class, is required prior
to the Company’s (or Nova’s) creation or issuance of any senior securities.
Conversion Rights. Each shares of series
N senior convertible preferred stock, plus all accrued and unpaid dividends thereon, shall be convertible, at the option of the holder
thereof, at any time and from time to time, into such number of fully paid and nonassessable shares of common stock determined by dividing
the stated value ($4.00 per share), plus the value of the accrued, but unpaid, dividends thereon, by a conversion price of $0.012 per
share (subject to standard adjustments in the event of any stock splits, stock combinations, stock reclassifications, dividends paid in
common stock, sales of substantially all assets, mergers, consolidations or similar transactions); provided that in no event shall the
holder of any series N senior convertible preferred stock be entitled to convert any number of shares that upon conversion the sum of
(i) the number of shares of common stock beneficially owned by the holder and its affiliates and (ii) the number of shares of common stock
issuable upon the conversion of the series N senior convertible preferred stock with respect to which the determination of this proviso
is being made, would result in beneficial ownership by the holder and its affiliates of more than 4.99% of the then outstanding common
stock. This limitation may be waived (up to a maximum of 9.99%) by the holder and in its sole discretion, upon not less than sixty-one
(61) days’ prior notice to the Company.
Redemption Rights. The Company may redeem
the series N senior convertible preferred stock at any time by paying in cash therefore a sum equal to 115% of the stated value of $4.00
per share, plus the amount of accrued and unpaid dividends and any other amounts due pursuant to the terms of the certificate of designation.
In addition, any holder may require the Company to redeem some or all of its shares of series N senior convertible preferred stock on
the same terms after a period of twelve months from the date of issuance; provided, however, that such redemption right shall only be
exercisable if the Company raises at least $5,000,000 or the common stock is trading on the Nasdaq Stock Market or the New York Stock
Exchange.
Series X Senior Convertible Preferred Stock
Ranking. The series X senior convertible
preferred stock ranks, with respect to the payment of dividends and the distribution of assets upon liquidation, (i) senior to all common
stock and each other class or series that is not expressly made senior to or on parity with the series X senior convertible preferred
stock; (ii) on parity with each class or series that is not expressly subordinated or made senior to the series X senior convertible preferred
stock; and (iii) junior to the series N senior convertible preferred stock, all indebtedness and other liabilities with respect to assets
available to satisfy claims against the Company and each class or series that is expressly made senior to the series X senior convertible
preferred stock.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Dividend Rights. Holders of series X senior
convertible preferred stock are entitled to dividends at a rate per annum of 10.0% of the stated value ($4.00 per share); provided that
upon an event of default (as defined in the certificate of designation for the series X senior convertible preferred stock), such rate
shall increase by 5% per annum. Dividends shall accrue from day to day, whether or not declared, and shall be cumulative. Dividends shall
be payable quarterly in arrears on each dividend payment date. At June 30, 2023, cumulative dividends on Series X Preferred Stock were
$115,068.
Liquidation Rights. Subject to the rights
of creditors and the holders of any senior securities, including the series N senior convertible preferred stock, or parity securities
(in each case, as defined in the certificate of designation), upon any liquidation of the Company or its subsidiaries, before any payment
or distribution of the assets of the Company (whether capital or surplus) shall be made to or set apart for the holders of junior securities
(as defined in the certificate of designation), including the common stock, each holder of outstanding series N senior convertible preferred
stock shall be entitled to receive an amount of cash equal to 100% of the stated value of $4.00 per share, plus an amount of cash equal
to all accumulated accrued and unpaid dividends thereon (whether or not declared) to, but not including the date of final distribution
to such holders.
Voting Rights. Holders of series X senior
convertible preferred stock do not have any voting rights; provided that, so long as any shares of series X senior convertible preferred
stock are outstanding, the affirmative vote of holders of a majority of the series X senior convertible preferred stock, which majority
must include Leonite Capital LLC so long as it holds any shares of series X senior convertible preferred stock, voting as a separate class,
shall be necessary for approving, effecting or validating any amendment, alteration or repeal of any of the provisions of the certificate
of designation or prior to the creation or issuance of any parity securities or new indebtedness (as defined in the certificate of designation);
provided that the foregoing shall not apply to any financing transaction the use of proceeds of which will be used to redeem the series
X senior convertible preferred stock and the warrants issued in connection therewith. In addition, the affirmative vote of holders of
66% of the series X senior convertible preferred stock, voting as a separate class, is required prior to the creation or issuance of any
senior securities.
Conversion Rights. Each shares of series
X senior convertible preferred stock, plus all accrued and unpaid dividends thereon, shall be convertible, at the option of the holder
thereof, at any time and from time to time, into such number of fully paid and nonassessable shares of common stock determined by dividing
the stated value ($4.00 per share), plus the value of the accrued, but unpaid, dividends thereon, by a conversion price equal to the lower
of (i) the lowest VWAP during the five (5) trading days immediately prior to the applicable conversion date and (ii) the price per share
paid in any subsequent financing (the “Fixed Price”). The Fixed Price is subject to standard adjustments in the event of any
stock splits, stock combinations, stock reclassifications, dividends paid in common stock, sales of substantially all assets, mergers,
consolidations or similar transactions, as well as a price based antidilution adjustment, pursuant to which, subject to certain exceptions,
if the Company issues common stock at a price lower than the Fixed Price, the Fixed Price shall decrease to such lower price. Notwithstanding
the foregoing, in no event shall the holder of any series X senior convertible preferred stock be entitled to convert any number of shares
that upon conversion the sum of (i) the number of shares of common stock beneficially owned by the holder and its affiliates and (ii)
the number of shares of common stock issuable upon the conversion of the series X senior convertible preferred stock with respect to which
the determination of this proviso is being made, would result in beneficial ownership by the holder and its affiliates of more than 4.99%
of the then outstanding common stock. This limitation may be waived (up to a maximum of 9.99%) by the holder and in its sole discretion,
upon not less than sixty-one (61) days’ prior notice to the Company.
Redemption Rights. Commencing on September
22, 2023, any holder may require the Company to redeem its shares by the payment in cash therefore of a sum equal to 100% of the stated
value of $4.00 per share, plus the amount of accrued and unpaid dividends and any other amounts due pursuant to the terms of the certificate
of designation; provided however, that in the event that the Company completes a public offering prior to the redemption date, then any
holder may only cause the Company to redeem any outstanding series X senior convertible preferred stock by paying such redemption price
in twelve (12) equal monthly installments with the first such payment due on the date that is six (6) months following the date that the
Company completes such public offering.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Non-redeemable Preferred Stock
Series A Preferred Stock
Each share of series A preferred stock is entitled
to a number of votes and converts to a number of shares equal to the sum of all shares of common stock and series B preferred stock issued
and outstanding, divided by the number shares of series A preferred stock held. Holders of series A preferred stock do not have any dividend,
liquidation or redemption rights.
Series B Preferred Stock
Each share of series B preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series B preferred stock is convertible into two (2)
shares of common stock (subject to adjustment for forward stock splits but not reverse stock splits). Holders of series B preferred stock
do not have any dividend, liquidation or redemption rights.
Series C Preferred Stock
Each share of series C preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series C preferred stock is convertible into 100,000
shares of common stock (subject to adjustment for forward stock splits but not reverse stock splits). If the Company lists on an exchange,
it has the right to repurchase these shares at a purchase price of $50,000 per share. Holders of series C preferred stock do not have
any dividend, liquidation or redemption rights.
Series D Preferred Stock
Each share of series D preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series D preferred stock is convertible into two (2)
shares of common stock. Holders of series D preferred stock do not have any dividend, liquidation or redemption rights.
Series E Preferred Stock
Each share of series E preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series E preferred stock is convertible into two (2)
shares of common stock. Holders of series E preferred stock do not have any dividend, liquidation or redemption rights.
Series F Preferred Stock
Each share of series F preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series F preferred stock is convertible into two (2)
shares of common stock. Holders of series F preferred stock do not have any dividend, liquidation or redemption rights.
Series F-1 Preferred Stock
Each share of series F-1 preferred stock is convertible
into two (2) shares of common stock. Holders of series F-1 preferred stock do not have any voting, dividend, liquidation or redemption
rights.
Series I Preferred Stock
Each share of series I preferred stock is entitled
to five (5) votes on all matters submitted to a vote of stockholders. Each share of series I preferred stock is convertible into two (2)
shares of common stock. Holders of series I preferred stock do not have any dividend, liquidation or redemption rights.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Series J Preferred Stock
Each share of series J preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series J preferred stock is convertible into two (2)
shares of common stock. Holders of series J preferred stock do not have any dividend, liquidation or redemption rights.
Series L Preferred Stock
Each share of series L preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series L preferred stock is convertible into two (2)
shares of common stock. Holders of series L preferred stock do not have any dividend, liquidation or redemption rights.
Series R Preferred Stock
Each share of series R preferred stock is entitled
to one (1) vote on all matters submitted to a vote of stockholders. Each share of series B preferred stock is convertible into one (1)
shares of common stock (subject to adjustment for forward stock splits but not reverse stock splits). Holders of series R preferred stock
do not have any dividend, liquidation or redemption rights.
Preferred Stock Transactions
During the six months ended June 30, 2023, the
Company executed the following transactions:
| · | On May 25, 2023, the Company issued 3,150
shares of series B preferred stock to Zia Choe, Interim Chief Financial Officer for $25,000. |
During the six months ended June 30, 2022, the
Company executed the following transactions:
| · | In the second quarter of 2022, 37,500 shares
of series D preferred stock were cancelled and exchanged for 37,500 shares
of series B preferred stock and 37,500
shares of series H preferred stock were cancelled and exchanged for 37,500 shares
of series B preferred stock. |
Common Stock
During the six months ended June 30, 2023, the
Company executed the following transactions:
| · | The Company issued 118,682,378 shares of common
stock upon conversion of certain convertible notes. |
The table below sets forth warrant activity for
the six months ended June 30, 2023 and 2022:
Schedule of warrant activity | |
| | | |
| | |
| |
Number of Warrants | | |
Weighted Average Exercise Price | |
Balance at January 1, 2023 | |
| 235,557,856 | | |
$ | 0.015 | |
Granted | |
| – | | |
| – | |
Exercised | |
| – | | |
| – | |
Forfeited | |
| (25,000 | ) | |
| – | |
Balance at June 30, 2023 | |
| 235,532,856 | | |
| 0.015 | |
Warrants Exercisable at June 30, 2023 | |
| 235,532,856 | | |
$ | 0.015 | |
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
As a result of the settlement agreement with Red
Rock on July 29, 2022, the Company required the previous owners to relinquish warrants for 25,000 shares of common stock. The certificate
of the 25,000 warrants were returned and cancelled during the second quarter of 2023. There was no impact on the consolidated financial
statements as of December 31, 2022.
| 13. | DISCONTINUED OPERATIONS |
The Company and the managers of AHI entered into
a resignation, release and buyback agreement and addendum, effective October 31, 2022, pursuant to which the managers purchased AHI in
exchange for returning 175,045 shares of series F preferred stock. There was a loss on disposal in the amount of $217,769 on October 31,
2022, which represented net assets and liabilities at the time of sale back.
The Company had no net liabilities of discontinued operations at June 30, 2023 and December 31, 2022. The Company had $0
and $36,935
of loss from discontinued operations for the three months ended June 30, 2023 and 2022, respectively. The Company had $0
and $35,542
of loss from discontinued operations for the six months ended June 30, 2023 and 2022, respectively.
Schedule of discontinued operations | |
| | | |
| | |
| |
Three Months Ended June 30, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Gain (Loss) from discontinued operations | |
| | | |
| | |
Revenue of AHI subsidiary | |
$ | – | | |
$ | 39,512 | |
Cost of sales of AHI subsidiary | |
| – | | |
| (18,614 | ) |
Selling, general and administrative expenses of AHI subsidiary | |
| – | | |
| (40,833 | ) |
Interest expense of Red Rock Investor Note | |
| – | | |
| (17,000 | ) |
Loss from discontinued operations | |
$ | – | | |
$ | (36,935 | ) |
| |
| | | |
| | |
| |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Gain (Loss) from discontinued operations | |
| | | |
| | |
Revenue AHI subsidiary | |
$ | – | | |
$ | 83,356 | |
Cost of sales AHI subsidiary | |
| – | | |
| (38,088 | ) |
Selling, general and administrative expenses AHI subsidiary | |
| – | | |
| (42,714 | ) |
Interest expense of Red Rock Investor Note | |
| – | | |
| (33,622 | ) |
Gain no change in estimate of AHI subsidiary | |
| – | | |
| (4,474 | ) |
Loss from discontinued operations | |
$ | – | | |
$ | (35,542 | ) |
| 14. | GOODWILL AND IDENTIFIABLE INTANGIBLE ASSETS, NET |
The following table shows the Company’s
goodwill balances by reportable segment. The Company reviews goodwill for impairment on a reporting unit basis annually and whenever events
or changes in circumstances indicate the carrying value of goodwill may not be recoverable. During the six months ended June 30, 2023
and 2022, the Company had no goodwill impairment.
The following table shows goodwill balances by
reportable segment:
Schedule of goodwill balances | |
| | | |
| | |
| |
Healthcare | | |
Total | |
Carrying value at December 31, 2022 | |
$ | 5,666,608 | | |
$ | 5,666,608 | |
Accumulated impairment | |
| – | | |
| – | |
Carrying value at June 30, 2023 | |
$ | 5,666,608 | | |
$ | 5,666,608 | |
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| 15. | COMMITMENTS AND CONTINGENCIES |
Leases
ASC 842, “Leases”, requires that a
lessee recognize the assets and liabilities that arise from operating leases, A lessee should recognize in the statement of financial
position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying
asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by
class of underlying asset not to recognize lease assets and lease liabilities. In transaction, lessees and lessors are required to recognize
and measure leases at either the effective date (the “effective date method”) or the beginning of the earliest period presented
(the “comparative method”) using a modified retrospective approach. Under the effective date method, the Company’s comparative
period reporting is unchanged. In contrast, under the comparative method, the Company’s date of initial application is the beginning
of the earliest comparative period presented, and the Topic 842 transition guidance is then applied to all comparative periods presented.
Further, under either transition method, the standard includes certain practical expedients intended to ease the burden of adoption. The
Company adopted ASC 842, January 1, 2020, using the effective date method and elected certain practical expedients allowing the Company
not to reassess:
| · | whether expired or existing contracts contain
leases under the new definition of a lease; |
| · | lease classification for expired or existing
leases; and |
| · | whether previously capitalized initial direct
costs would qualify for capitalization under Topic 842. |
The Company also made the accounting policy decision
not to recognize lease assets and liabilities for leases with a term of 12 months or less.
The Company recorded operating lease expense
of $56,378 and
$34,305
for the three months ended June 30, 2023 and 2022, respectively and the Company recorded operating lease expense of $134,230
and $170,150 for
the six months ended June 30, 2023 and 2022, respectively.
The Company has operating leases with future
commitments as follows:
Schedule of property leases | |
| | |
June 30, | |
Amount | |
2024 | |
$ | 126,752 | |
2025 | |
| 32,205 | |
Total | |
$ | 158,957 | |
Employees
The Company agreed to pay $360,000 per year and
$200,000 of targeted annual incentives to the Chief Executive Officer based on his employment agreement since July 1, 2020, of which currently
50% is paid in cash and 50% is accrued. The total outstanding accrued compensation as of June 30, 2023 and December 31, 2022 were $2,025,500
and $1,870,500, respectively.
The Company agreed to pay $360,000 per year
and $200,000 of targeted annual incentives to the Chairman of the Board based on his employment agreement since July 1, 2020, of
which currently 50% is paid in cash and 50% is accrued. The total outstanding accrued compensation as of June 30, 2023 and December
31, 2022 were $2,042,000
and $1,863,000,
respectively.
The Company agreed to pay $156,000 per year to
the previous Chief Financial Officer based on his amended employment agreement executed on May 15, 2021. The total outstanding accrued
compensation as of June 30, 2023 and December 31, 2022 was $17,057.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
The Company entered into a Management Agreement
effective May 31, 2021 for compensation to the principals of Nova in the form of an annual base salaries of $372,000
to one of the three doctors, $450,000
to the second, and $372,000
to the third doctor. Collectively, as a group, such principals will receive an annual cash bonus and stock equity set forth below,
which will be conditioned upon the Company achieving 100% of the annual objectives of financial performance goals as set forth below.
Schedule of annual objectives of financial performance |
|
|
|
Year |
Minimum Annual Nova EBITDA |
Cash Annual Bonus |
Series J Preferred Stock |
2022 |
$2.0M |
$120,000 |
120,000 Shares |
2022 |
$2.4M |
$150,000 |
135,000 Shares |
2023 |
$3.7M |
$210,000 |
150,000 Shares |
2024 |
$5.5M |
$300,000 |
180,000 Shares |
2025 |
$8.0M |
$420,000 |
210,000 Shares |
From time to time, the Company may become involved
in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties,
and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. Management is
not currently aware of any such legal proceedings or claims that it believes will have a material adverse effect on the Company’s
business, financial condition, or operating results.
The Company has three reportable operating segments
as determined by management using the “management approach” as defined by the authoritative guidance on Disclosures
about Segments of an Enterprise and Related Information:
|
(1) |
Tax Resolution Services (Platinum Tax) |
|
(2) |
Real Estate (Edge View) |
These segments are a result of differences in
the nature of the products and services sold. Corporate administration costs, which include, but are not limited to, general accounting,
human resources, legal and credit and collections, are partially allocated to the three operating segments. Other revenue consists of
nonrecurring items.
The Affordable Housing segment leases and sells
mobile homes as an option for a homeowner wishing to avoid large down payments, expensive maintenance costs, large monthly mortgage payments
and high property taxes and insurance which is a common trait of brick-and-mortar homes. Additionally, if bad credit is an issue preventing
potential homeowners from purchasing a traditional house, the Company will provide a "lease to own" option so people secure
their family home.
The Tax Resolution Services segment provides tax
resolution services to individuals and companies that have federal and state tax liabilities. The Company collects fees based on efforts
to negotiate and assist in the settlement of outstanding tax debts.
The Real Estate segment consists of Edge View,
a real estate company that owns five (5) acres zoned medium density residential (MDR) with 12 lots already platted, six (6) acres zoned
high-density residential (HDR) that can be platted in various configurations to meet current housing needs, and twelve (12) acres
zoned in Lemhi County as Agriculture that is available for further annexation into the City of Salmon for development, as well as a common
area for landowners to view wildlife, provide access to the Salmon River and fishing in a two (2) acre pond.
The Healthcare segment provides a full range of
diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments,
and nerves.
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
Schedule of segment reporting | |
| | | |
| | |
| |
June 30, 2023 | | |
December 31, 2022 | |
Assets: | |
| | | |
| | |
Financial Services | |
$ | 2,820 | | |
$ | 8,577 | |
Healthcare | |
| 15,455,454 | | |
| 12,692,531 | |
Real Estate | |
| 589,331 | | |
| 592,557 | |
Others | |
| 5,914 | | |
| 59,692 | |
Consolidated assets | |
$ | 16,053,519 | | |
$ | 13,353,357 | |
| |
Three Months Ended June 30, | |
| |
2023 | | |
2022 | |
Revenues: | |
| | |
| |
Financial Services | |
$ | 118,304 | | |
$ | 472,014 | |
Healthcare | |
| 3,364,506 | | |
| 2,619,218 | |
Consolidated revenues | |
$ | 3,482,810 | | |
$ | 3,091,232 | |
| |
| | | |
| | |
Cost of Sales: | |
| | | |
| | |
Financial Services | |
$ | 21,297 | | |
$ | 112,776 | |
Healthcare | |
| 1,081,689 | | |
| 983,842 | |
Consolidated cost of sales | |
$ | 1,102,986 | | |
$ | 1,096,618 | |
| |
| | | |
| | |
Income (Loss) from operations from subsidiaries | |
| | | |
| | |
Financial Services | |
$ | (43,269 | ) | |
$ | 11,361 | |
Healthcare | |
| 2,106,551 | | |
| 1,481,055 | |
Real Estate | |
| (1,743 | ) | |
| (1,688 | ) |
Income from operations from subsidiaries | |
$ | 2,061,539 | | |
$ | 1,490,728 | |
| |
| | | |
| | |
Loss from operations from Cardiff Lexington | |
$ | (355,369 | ) | |
$ | (388,717 | ) |
Total income from operations | |
$ | 1,706,170 | | |
$ | 1,102,011 | |
| |
| | | |
| | |
Income (Loss) before taxes | |
| | | |
| | |
Financial Services | |
$ | (43,810 | ) | |
$ | (45,540 | ) |
Healthcare | |
| 1,378,445 | | |
| 51,136 | |
Real Estate | |
| (1,743 | ) | |
| (2,416 | ) |
Corporate, administration and other non-operating expenses | |
| (516,814 | ) | |
| (65,006 | ) |
Consolidated income (loss) before taxes | |
$ | 816,078 | | |
$ | (61,826 | ) |
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(UNAUDITED)
| |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
Revenues: | |
| | |
| |
Financial Services | |
$ | 272,703 | | |
$ | 936,857 | |
Healthcare | |
| 6,070,905 | | |
| 5,051,525 | |
Consolidated revenues | |
$ | 6,343,608 | | |
$ | 5,988,382 | |
| |
| | | |
| | |
Cost of Sales: | |
| | | |
| | |
Financial Services | |
$ | 48,126 | | |
$ | 325,222 | |
Healthcare | |
| 2,037,983 | | |
| 1,887,624 | |
Consolidated cost of sales | |
$ | 2,086,109 | | |
$ | 2,212,846 | |
| |
| | | |
| | |
Income (Loss) from operations from subsidiaries | |
| | | |
| | |
Financial Services | |
$ | (87,256 | ) | |
$ | (90,120 | ) |
Healthcare | |
| 3,384,790 | | |
| 2,784,403 | |
Real Estate | |
| (1,840 | ) | |
| (2,513 | ) |
Income from operations from subsidiaries | |
$ | 3,295,694 | | |
$ | 2,691,770 | |
| |
| | | |
| | |
Loss from operations from Cardiff Lexington | |
$ | (875,962 | ) | |
$ | (868,276 | ) |
Total income from operations | |
$ | 2,419,732 | | |
$ | 1,823,494 | |
| |
| | | |
| | |
Income (Loss) before taxes | |
| | | |
| | |
Financial Services | |
$ | (89,300 | ) | |
$ | |